Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 348, pseudogene (RNU6-348P) is a member of the U6 small nuclear RNA (snRNA) pseudogene family[1][3][5][7][9]. Pseudogenes are DNA sequences that resemble functional genes but are typically nonfunctional due to disabling mutations or lack of regulatory sequences. RNU6-348P derives from U6 snRNA, which is essential for pre-mRNA splicing as part of the spliceosome; however, the “pseudogene” status signifies RNU6-348P does *not* encode a functional RNA product and is not involved in splicing or other cellular functions[2][3][5][7][9]. Genomic studies categorize such snRNA pseudogenes as molecular fossils of past retrotransposition events and use them as markers for genome evolution, but they lack protein-coding or direct regulatory activity[2][4]. There are no known pharmacological, therapeutic, or diagnostic applications for RNU6-348P, nor is it regarded as a receptor, enzyme, or other classical drug target[3][5][7][9].
None (not a drug target; no known mechanism of action)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 348, pseudogene (RNU6-348P).